

# Drug-Induced Congenital Defects

## Strategies to Reduce the Incidence

Marco De Santis, Brigida Carducci, Anna Franca Cavaliere, Lidia De Santis,  
Gianluca Straface and Alessandro Caruso

Telefono Rosso – Teratogen Information Service, Department of Obstetrics and Gynaecology,  
Catholic University of Sacred Heart, Rome, Italy

### Contents

Abstract	889
1. Controlled Administration of Known Teratogenic Drugs	890
1.1 Thalidomide	891
1.2 Retinoids	892
1.2.1 Isotretinoin	892
1.2.2 Etretinate	893
1.2.3 Topical Retinoid	893
1.3 High Doses of Retinol (Vitamin A)	893
2. Use of Alternative Pharmacological Therapies in the Pre-Conception Period	894
2.1 Bipolar Disorder/Depression	894
2.1.1 Lithium	894
2.1.2 Tricyclic Antidepressants	894
2.1.3 Haloperidol	894
2.2 Epilepsy	894
2.2.1 Phenytoin	895
2.2.2 Carbamazepine	895
2.2.3 Valproic Acid (Sodium Valproate)	895
2.2.4 Barbiturates	895
2.3 Hyperthyroidism	895
3. Appropriate Substitution Therapy During Pregnancy	896
3.1 Diabetes Mellitus	896
3.2 Thrombolysis	896
3.3 Hypertension	896
4. Controlled Administration of Drugs During Pregnancy: Pharmacological Effects versus Gestation Period	896
4.1 Chemotherapy	897
4.2 Nonsteroidal Anti-Inflammatory Drugs	897
4.3 Benzodiazepines	897
5. Conclusions	897

### Abstract

Approximately 1% of congenital anomalies relate to pharmacological exposure and are, in theory, preventable. Prevention consists of controlled administration of drugs known to have teratogenic properties (e.g. retinoids, thalidomide). When possible, prevention could take the form of the use of alternative pharmacological therapies during the pre-conception period for certain specific pathol-

ogies, selecting the most appropriate agent for use during pregnancy [e.g. haloperidol or a tricyclic antidepressant instead of lithium; anticonvulsant drug monotherapy in place of multitherapy; propylthiouracil instead of thiamazole (methimazole)], and substitution with the most suitable therapy during pregnancy (e.g. insulin in place of oral antidiabetics; heparin in place of oral anticoagulants;  $\alpha$ -methyl dopa instead of ACE inhibitors). Another strategy is the administration of drugs during pregnancy taking into account the pharmacological effects in relation to the gestation period (e.g. avoidance of chemotherapy during the first trimester, avoidance of nonsteroidal anti-inflammatory drugs in the third trimester, and avoidance of high doses of benzodiazepines in the period imminent to parturition).

The incidence of congenital defects is estimated to be approximately 5% of all births. A congenital defect is generally defined as an anatomic anomaly but may also be a metabolic or functional (including mental retardation) anomaly caused by a genetic alteration or by a physical, chemical or infectious agent reacting during prenatal life.<sup>[1]</sup>

It is possible to define the cause of a congenital defect in only an estimated 10% of cases while for the remaining 90% the origin remains unknown. Among identifiable causes it is probable that drugs contribute to 1% or less of all congenital defects. The importance of drug-induced malformations is that they are all potentially foreseeable.<sup>[1]</sup> Furthermore, knowledge of the teratogenic risks inherent with certain drugs not only renders it possible to reduce the incidence of congenital defects by correct and medically controlled use of such agents, but also contributes to a reduction in the number of abortions performed because of fear of defects or incorrect information regarding presumed and untenable risks.

It is vital that evidence from animal models be taken into account when assessing teratogenic risk linked with specific drugs, especially data from primates. Even so, it is obvious that only direct experience in humans will furnish conclusive data on the safety or teratogenic nature of a specific substance; in this sense, results of controlled studies with numerically significant cohorts and of controlled cases are of particular value.<sup>[2,3]</sup> Teratogen Information Services (TIS), operating in many countries, have provided over a period of time an important

contribution to the improvement of knowledge by reporting numerous cases of women who are more frequently exposed to certain pharmaceuticals during pregnancy.<sup>[4]</sup>

In clinical practice, drugs are classified on the basis of their risk to the fetus, and one of the definitions of risk is that used by the US Food and Drug Administration (FDA) which takes into account animal studies, controlled trials in pregnant women and the risk/benefit ratio resulting from use (table I).<sup>[5]</sup> Considering that a drug should only be used during pregnancy when absolutely necessary and is of proven efficacy, the first step in a correct strategy for reducing drug-induced congenital defects is the individualisation of drugs recognised as teratogenic and ensuring their controlled administration in women of fertile age. The second step, in the event of necessary chronic therapy with teratogenic drugs, could be suspension or the modification of treatment by using pharmaceutical preparations more suitable for use during pregnancy as well as during the pre-conception phase. The third step consists in using, during pregnancy, drugs that are safer for the fetus and still efficacious for the mother. A fourth and final step would be to take into account the effects of the drugs during the different stages of the gestation period, avoiding their use during critical phases, such as the embryonic or peripartum periods.

### **1. Controlled Administration of Known Teratogenic Drugs**

Considering that approximately 40 to 90%<sup>[4,6]</sup>

**Table I.** Definitions used for pregnancy risk categories as defined by the US Food and Drug Administration<sup>[5]</sup>

Category A	Controlled studies in women fail to demonstrate a risk to the fetus in the first trimester (and there is no evidence of a risk in later trimesters), and the possibility of fetal harm appears remote
Category B	Either animal reproduction studies have not demonstrated a fetal risk but there are no controlled studies in pregnant women or animal reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the first trimester (and there is no evidence of a risk in later trimesters)
Category C	Either studies in animals have revealed adverse effects on the fetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the fetus
Category D	There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g. if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective)
Category X	Studies in animals or human beings have demonstrated fetal abnormalities or there is evidence of fetal risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant

of pregnant women consume pharmacological substances (and self administration is not rare), all teratogenic drugs should be prescribed with extreme caution in women of fertile age (table II). The leaflet accompanying a drug that is supplied by the pharmaceutical company should contain clear and precise information, and the prescribing specialist must also provide appropriate information. Information should include not only the possible risks but also the waiting periods before an eventual conception.

Among the most known teratogenic pharmaceuticals are thalidomide, retinoids and high doses of retinol (vitamin A).

### 1.1 Thalidomide

Thalidomide is the most well known teratogenic. Developed in the 1950s as a sleeping drug it was also used for prevention of nausea during pregnancy. Thalidomide was banned early in the 1960s when it was found to be the cause of deformed limbs in the children of mothers who were administered this drug during early pregnancy.<sup>[7-9]</sup> It has been calculated that approximately 8 thousand neonates worldwide were born with deformations due to thalidomide.<sup>[7-9]</sup> This drug is now under investigation for treatment of AIDS, tuberculosis, Behçet's syndrome, graft-versus-host-diseases, treatment of some symptoms of Hansen's disease or leprosy, and other illnesses.<sup>[10-13]</sup> In July 1998, the FDA approved its use in the treatment of a skin pathol-

ogy, i.e. leprosy erythema nodosum, a complication in leprosy.<sup>[13]</sup> Among the adverse effects on the human fetus are: phocomelia, amelia, hypoplasia, congenital cardiac defects, renal malformation, gastrointestinal malformations, cryptorchism, abducent paralysis, deafness, microtia, anotia, retarded growth, mental retardation and autism.<sup>[7-9]</sup> The risk of teratogenesis is approximately 20% when drug exposure occurs between the 34th and 50th day of gestation.<sup>[14]</sup> A 'safe' dose during pregnancy has not yet been established and cases of embryopathy have been observed even at dosages of 50 mg/day when the drug is administered during the critical period.<sup>[14]</sup> It should be noted in regard to thalidomide that there is a wide variability in susceptibility as demonstrated in different species in relation to teratogenic effects and there is a strict relationship between exposure time and the presence and type of defect.

Taking into account the definite teratogenic effects of thalidomide the FDA provides recommendations and regulations for controlled use of this drug. Among the recommendations for preventing fetal drug exposure, it is interesting to note the advice for a reliable method of contraception and periodical tests for pregnancy for patients of fertile age, and the completeness of information which also includes informed consent. A programme known as System for Thalidomide Education and Prescribing Safety (STEPS) has been established for this drug.<sup>[10,13,15]</sup> In Brazil, where thalidomide is mar-

keted for treatment of leprosy, 33 new cases of embryopathy ascribable to exposure to this pharmaceutical have recently been reported.<sup>[13]</sup>

## 1.2 Retinoids

Retinoids are retinol (vitamin A) analogues used in the treatment of dermatological pathologies such as severe acne and psoriasis. They are teratogenic in experimental animals and humans. In fact, they are recognised as the possible cause of miscarriages, congenital structural anomalies, especially involving the CNS, and consequently, psychomotor and intellectual retardation. Therefore, they are contra-

indicated for administration during pregnancy and in the pre-conception period. Due to their lipid-soluble characteristic, permanence in the body is of extremely long duration after administration. This means that pregnancy must be planned following their use and it is obligatory that the correct information on teratogenic risks is available. Among the retinoids the most well known from a clinical viewpoint are isotretinoin (13-*cis*-retinoic acid), etretinate and the topical retinoids, e.g. adapalene and tretinoin.

### 1.2.1 Isotretinoin

Isotretinoin is an isomer of retinol, used in treatment of severe cystic acne. Well before its approval

**Table II.** Drugs known to be human teratogens

Drugs	Most frequent anomalies
ACE inhibitors	Renal damage, bone defects, oligohydramnios, IUGR (following second and third trimester exposure)
Aminopterin and derivatives	CNS, limbs, craniofacial defects
Benzodiazepines	Neonatal withdrawal syndrome, apnoea, hypotonia, hypothermia (following pre-partum exposure)
Busulfan	IUGR, craniofacial, cardiac, internal organs
Carbamazepine	Neural tube defects (1% incidence)
Cyclophosphamide	Miscarriage, absent thumbs, cleft palate, multiple eye defects
Coumarin derivatives	Nasal hypoplasia, chondrodysplasia punctata, bone, facial and CNS defects (10% incidence following first trimester exposure)
Diethylstilbestrol	Clear cell vaginal or cervical adenocarcinoma
Diphenylhydantoin	Facial dysmorphism, skeletal abnormalities, cleft palate, neuroblastoma, microcephaly (5 to 10% incidence)
Ergotamine (high doses)	NTD, intestinal atresia
Hormones with androgenous activity	Masculinisation of external female genitals
Iodides and Iodine-131	Goitre, hypothyroidism
Kanamycin	Auditory function disturbance
Lithium	Cardiac defects (<2% incidence)
Misoprostol	Agnesia of limbs, cranium defects, Moebius syndrome, miscarriage
Nonsteroidal anti-inflammatory drugs	Oligohydramnios, precocious closure of Botallo's duct, haemorrhage, NEC (following third trimester exposure)
Penicillamine	Cutis laxa (<1% incidence)
Phenytoin	Facial and CNS defects
Retinoids (systemic) [isotretinoin and etretinate]	Miscarriage, craniofacial, cardiac and upper/lower limbs, CNS. For isotretinoin: 18% risk of malformations; 40% risk of miscarriage
Streptomycin	Auditory function disturbance
Thalidomide	Limb defects, cardiac, renal, gastrointestinal malformations, deafness, ocular defects (20% risk during 34 to 50th gestation day)
Tetracycline	Deciduous tooth enamel defect (occurs in 50% of fetuses exposed)
Thiamazole (methimazole)	Scalp defects (1 to 5% incidence)
Trimethadione	IUGR cardiac anomalies
Valproic acid (sodium valproate)	NTD (1 to 2% incidence)

**IUGR** = intrauterine growth retardation; **NEC** = necrotising enterocolitis; **NTD** = neural tube defects.

in 1982 for use in humans the teratogenic effects in experimental animals were known.<sup>[16]</sup> Data available in humans to date indicate that exposure at 0.4 to 1.5 mg/kg/day of isotretinoin during the first week of pregnancy causes miscarriage in 22% of cases and congenital malformations in 18%.<sup>[17]</sup> The most frequently observed malformations are characterised by defects of the CNS (microcephaly, hydrocephaly, encephalocele); the ear (microtia, stenosis or atresia of the external auditory tube, dysmorphism of the ears and low implant); the heart (conotruncus defects, aortic coarctation, ventricular septal defects). Facial dysmorphism is also present in the majority of cases. Furthermore, it seems that apparently healthy neonates could present with functional defects well after the neonatal period (e.g. blindness, deafness, intellectual deficit).<sup>[18-27]</sup> Isotretinoin is therefore a potent teratogen. Since a high percentage of users are women of fertile age it is necessary to prescribe this substance only after excluding any possibility of pregnancy, and then initiating an efficacious contraceptive regimen which should continue for at least 1 month after suspension of the drug.<sup>[28,29]</sup> Before prescribing isotretinoin, a pregnancy prevention plan and full information on the teratogenic risks involved are necessary.<sup>[30-34]</sup>

### 1.2.2 Etretinate

Etretinate is a retinoid used in the treatment of psoriasis.<sup>[35,36]</sup> It persists in the body for an extremely long period after administration; it has been found present in the blood more than 2 years after cessation of therapy.<sup>[37-40]</sup> However, the duration of the teratogenic effect of the drug remains unknown.<sup>[19,39,40]</sup> Avoidance of conception is in any case advised for at least 6 to 12 months after conclusion of therapy.<sup>[38]</sup> Etretinate is teratogenic in experimental animals at doses similar or higher than those used in humans. Studies in humans carried out to date have associated etretinate with malformations at CNS level (spina bifida, encephalocele), malformations of the limbs and craniofacial anomalies.<sup>[16,41-44]</sup>

### 1.2.3 Topical Retinoids

Topical retinoid preparations are employed in the treatment of various dermatological patholo-

gies as well as for cosmetic use. Published information on pregnancy outcomes with congenital anomalies following exposure to topical retinoids is limited to very few case reports.<sup>[45-49]</sup> Even if controlled studies have not demonstrated a potential connection between use of topical retinoids and fetal malformation,<sup>[50,51]</sup> we recommend that their use be discouraged during pregnancy and the pre-conception period. In the event of exposure during pregnancy, ultrasound surveillance for typical signs of retinoic acid embryopathy is recommended.

### 1.3 High Doses of Retinol (Vitamin A)

Since teratogenic effects from retinoids are acknowledged, there is a strong suspicion in regard to the possibility of teratogenic risk from retinol at high doses.<sup>[41,52,53]</sup> This is an essential lipid-soluble nutrient naturally present in a variety of food products and necessary for the maintenance of tissues and functions. The daily requirement of retinol during pregnancy, according to recommendations by the Food Agriculture Organization/World Health Organization, is 3300 IU/day. The Teratology Society advises not to exceed dosages of 8000 IU/day during pregnancy.<sup>[54]</sup> This vitamin has a long half-life and is accumulative.<sup>[55]</sup> Teratology studies in animals show a dose-dependent increase in the incidence of fetal death and malformations, in particular craniofacial and cardiac defects. Up to 1986 the FDA received 18 reports of teratogenic effects from high dosages of retinol (18 000 to 150 000 IU/day) with patterns similar to those reported in association with retinoids (cardiac and craniofacial anomalies).<sup>[56]</sup> These results contrast with a collaborative European study in 312 neonates exposed to high doses of retinol (median 50 000 IU) where no type of malformation was observed.<sup>[57]</sup> In the light of the above and despite studies in laboratory animals, and the equivalence between retinoids and retinol, there is no definite demonstration of teratogenic effect. Nonetheless, the American Society of Teratology recommends, until further information becomes available, that women in fertile age should not consume retinol supplements containing more than 8000 IU/day

and pharmaceutical companies should reduce the dose of retinol to a maximum of 5000 to 8000IU per dosage unit. Furthermore, since the average balanced diet contains about 7000 to 8000IU daily of retinol, this should be taken into consideration when recommending a supplement. In cases of high doses of retinol, women of fertile age must be informed of the possible risks connected with a pregnancy that could commence during treatment, and should be encouraged to avoid conception. Pregnancies where there is known exposure to high doses of retinol during the first months of pregnancy must be regularly followed-up by careful ultrasound surveillance.

## 2. Use of Alternative Pharmacological Therapies in the Pre-Conception Period

Certain maternal pathologies require chronic therapy that is impossible to delay until after the pregnancy. Taking for granted that during a pregnancy it is not advisable to make therapeutic changes that could put the mother's health at risk, during the pre-conception phase it is possible to make excellent choices of drugs that, while ensuring good maternal treatment, involve minor risk for the fetus.

### 2.1 Bipolar Disorder/Depression

#### 2.1.1 Lithium

Women requiring long term lithium therapy for bipolar disorder illustrate the problems associated with chronic treatment. Cardiovascular malformations, in particular Ebstein's anomaly, have occurred in approximately 2% or less of neonates when the mothers underwent lithium carbonate therapy during the pregnancy.<sup>[58-64]</sup> Neonatal goitre and nephrogenic diabetes insipidus, cardiac arrhythmia, congestive cardiac failure and floppy infant syndrome have been observed in neonates of women who were treated with lithium.<sup>[62,65,66]</sup> When lithium treatment is indispensable throughout pregnancy, maternal serum concentrations should be maintained at lowest possible levels and monitoring is required at least once a month for the first half of the gestation period, then weekly until after

delivery. Dose changes should be limited and prenatal diagnosis by fetal ultrasound and, in particular, echocardiography should be advised. In anticipation of a pregnancy, substitution therapy with drugs that are much safer in pregnant patients should be attempted in well-selected individuals under the direct supervision of a specialist.

#### 2.1.2 Tricyclic Antidepressants

Providing clinical conditions permit, some alternatives to lithium can be taken into consideration. An alternative could be a tricyclic antidepressant which represents the treatment of choice for depression during pregnancy (i.e. imipramine and amitriptyline). No experimental animal data, nor the extensive epidemiological studies in humans, have provided any evidence of an association between their use and specific birth defects. Use of antidepressants in early pregnancy has not demonstrated any significant risk to the baby that can be detected during the neonatal period. Only sporadic indications regarding anomalies in women who used such drugs during pregnancy are found in literature and these do not provide any valid evidence of association.<sup>[67-73]</sup>

#### 2.1.3 Haloperidol

Haloperidol is a high potency antipsychotic drug that may be an alternative to lithium for anti-manic treatment.<sup>[60]</sup> No increased teratogenic risk has been reported; however, there is a risk of tardive dyskinesia in the mother and transient extrapyramidal reaction in the neonate.<sup>[74-76]</sup>

### 2.2 Epilepsy

Epilepsy is another condition requiring chronic therapy. There is a doubling or even 3-fold increase in incidence of congenital abnormalities among babies born to women with epilepsy. Even if epilepsy itself may be a contributing factor, the incidence of congenital malformations has been found to be higher in mothers with epilepsy who received anticonvulsants than in nontreated ones.<sup>[77]</sup> The risk is even greater for neonates born to women treated with multiple therapies compared with those receiving monotherapy.<sup>[78-80]</sup> It is therefore highly

recommended that women with epilepsy who are of fertile age receive: pre-conception counselling, folic acid supplementation, optimal control of seizure activity and monotherapy with the most suitable anticonvulsant drug at the lowest effective dose.<sup>[81]</sup>

No major anticonvulsant drug, i.e. phenytoin, carbamazepine, valproic acid (sodium valproate) or barbiturate, can be considered absolutely safe and free of teratogenic effects.

### **2.2.1 Phenytoin**

The 'fetal hydantoin syndrome' will occur in about 10% of neonates born to women with epilepsy who receive phenytoin therapy during pregnancy.<sup>[82-85]</sup> The most common features of this syndrome include ocular hypertelorism, flat nasal bridge, and distal digital hypoplasia with nail hypoplasia. Nonetheless, some controversy with regard to the phenytoin syndrome exists.<sup>[82-85]</sup> The possibility of a minimum increase in the risk of neuroblastoma and other neoplasms has been observed in babies whose mothers had been administered phenytoin during the embryogenetic phase.<sup>[86-88]</sup>

### **2.2.2 Carbamazepine**

Neural tube defects in neonates of women who received carbamazepine treatment during pregnancy have been observed with increased frequency.<sup>[89-93]</sup> In fact, the incidence of spina bifida ranged from 0.6 to 1.7% in cohort and prospective studies.<sup>[94,95]</sup>

### **2.2.3 Valproic Acid (Sodium Valproate)**

An association with spina bifida has been found when mothers undergo therapy with valproic acid during the first trimester of pregnancy. This finding is supported by many epidemiological studies and clinical case reports. The estimate of risk is approximately 2%.<sup>[79,96-102]</sup> In case of valproic acid therapy, divided doses are preferred to avoid high plasma concentrations.<sup>[100-103]</sup>

### **2.2.4 Barbiturates**

It seems that the risk of congenital anomalies does not significantly increase in women with epilepsy treated with phenobarbital (phenobarbitone) monotherapy.<sup>[71,104]</sup> In fact, in reference to those studies investigating the increased risk of congenital malformations in untreated patients with epilepsy, in particular, facial malformations and congenital heart defects, it may be hypothesised that the underlying disease rather than the treatment is the cause of the defects. However, there have been indications of an association with cardiovascular malformations and some types of barbiturates, and a long term negative effect on cognitive performances has been referred in regard to phenobarbital.<sup>[80,102,105-109]</sup>

ital malformations in untreated patients with epilepsy, in particular, facial malformations and congenital heart defects, it may be hypothesised that the underlying disease rather than the treatment is the cause of the defects. However, there have been indications of an association with cardiovascular malformations and some types of barbiturates, and a long term negative effect on cognitive performances has been referred in regard to phenobarbital.<sup>[80,102,105-109]</sup>

## **2.3 Hyperthyroidism**

Hyperthyroidism is another example of pathology during pregnancy requiring chronic pharmacological treatment.

Thionamides [propylthiouracil and thiamazole (methimazole)] are drugs used in the treatment of hyperthyroidism during pregnancy. While both are capable of crossing the placental barrier, this is inferior in the case of propylthiouracil. Recent studies have not shown any differences in therapeutic efficacy between propylthiouracil and thiamazole.<sup>[110]</sup> No differences have been found in fetal thyroid function. Follow-ups in children born to mothers treated with thionamides during pregnancy did not show any damaging effects on somatic or psychological growth or intellectual development.<sup>[110]</sup> However, what renders propylthiouracil the drug of choice as compared with thiamazole is that at least 19 cases of congenital aplasia of the skin of the scalp were found in neonates of women who had been treated with the latter agent (1 to 5%).<sup>[111-113]</sup> An association has not, however, been clearly demonstrated since hyperthyroidism could in itself increase the risk of congenital defects. Recently an unusual pattern of malformations was reported in some babies born to mothers exposed to thiamazole or carbimazole during pregnancy, and this has led to the suggestion of a rare embryopathology due to thiamazole.<sup>[114]</sup> This phenotype includes choanal and oesophageal atresia, scalp defects, minor facial anomalies and psychomotor delay.<sup>[115]</sup>

### 3. Appropriate Substitution Therapy During Pregnancy

#### 3.1 Diabetes Mellitus

Insulin is the drug of choice for diabetes mellitus during pregnancy.<sup>[5]</sup> Malformation rate ranges from 2- to 6-times that of the general population in the children of pregnant women with diabetes mellitus.<sup>[116-118]</sup> Malformations are diverse and multiple, the most common being cardiac and neural tube defects, followed by skeletal, gastrointestinal, and urinary tract abnormalities. Malformations occur during organogenesis, frequently before pregnancy is recognised, and are correlated to metabolic control. Women with these metabolic disorders who are planning pregnancy should be ensured of rigid surveillance of glycometabolic equilibrium from the pre-conception phase and throughout the pregnancy.<sup>[119-124]</sup>

Oral antidiabetics are not indicated during pregnancy because adequate control of glycaemia cannot be obtained with these agents during pregnancy and insulin release from the fetal pancreas may determine a higher risk of fetal macrosomia and high maternal and fetal morbidity.<sup>[5]</sup>

#### 3.2 Thrombolysis

Some maternal conditions (cardiac prosthetic valve, arterial or venous thrombosis) require use of anticoagulant therapies which can cause particular problems during pregnancy with regard to both efficacy of the thromboprophylaxis and fetal risk. Oral anticoagulants such as coumarin derivatives are more efficacious than heparin in reducing maternal risk, but their use during pregnancy is associated with various fetal-neonatal problems because they cross the placental barrier.<sup>[125]</sup>

Related fetal adverse effects of oral anticoagulants consist in intrauterine growth retardation (IUGR), stillbirth, psychomotor delay, hypotonia, convulsions, nasal underdevelopment and abnormal calcification of epiphyseal bone areas (chondrodysplasia punctata), CNS and eye abnormalities and haemorrhage.<sup>[126-131]</sup> Teratogenic risk of oral anticoagulants is equal to 10% during the first

trimester, with a more critical period between weeks 6 to 9 gestation and the risk is 3 to 5% during the second and third trimesters.<sup>[5,132,133]</sup> During pregnancy the best anticoagulant treatment regimen consists of replacing oral anticoagulant therapy with heparin from the beginning of pregnancy to the 16th week, then returning to oral anticoagulants up to the 36th week and again replacing with heparin therapy until delivery.<sup>[125]</sup>

#### 3.3 Hypertension

Another maternal pathology necessitating treatment during pregnancy is high-risk chronic hypertension. The characteristics of an antihypertensive drug for use during pregnancy are efficacy, lack of negative effects on uterus-placenta circulation and renal flow, lack of short and long term effects on fetus-neonate (teratogenic, neurological, reduced capacity for stress adaptation). To date, only  $\alpha$ -methyldopa responds to these requisites.<sup>[134]</sup> Other drugs may be used in alternative during the more advanced stages of the pregnancy such as,  $\beta$ -adrenergic blockers, and calcium channel antagonists. ACE inhibitors are contraindicated due to adverse fetal effects after exposure during the second and third trimesters. These effects are: insufficient ossification of head bones, kidney damage, oligohydramnios, lung hypoplasia, IUGR.<sup>[135-145]</sup> The angiotensin II inhibitors are also associated with such effects and should be avoided during pregnancy.<sup>[146]</sup>

### 4. Controlled Administration of Drugs During Pregnancy: Pharmacological Effects versus Gestation Period

The majority of drugs may be used during pregnancy, even if it is a good rule to avoid use during embryogenesis unless the therapy is absolutely necessary or involves well-controlled treatment with drugs with ample available data. Pharmacological treatments exist that are particularly damaging for the fetus during embryogenesis or during the peripartum period. Such drugs include: antitumour therapy during the first trimester, nonsteroidal anti-inflammatory drugs (NSAIDs) during the third, or



high doses of benzodiazepines imminent to partum.

#### 4.1 Chemotherapy

The decision to carry out chemotherapy during pregnancy must consider the need for therapy for the mother and possible risks for the fetus, and this must be taken into account for the duration of the pregnancy. Antineoplastic agents have an effect on rapidly proliferating cell populations, so are potentially dangerous to the growing fetus. Administration may lead to first trimester miscarriage or congenital malformations (14 to 17%) and later, to retarded growth and fetal death. Whenever possible, it is safer to delay such therapies until after the first trimester of pregnancy with benefits which appear similar to those obtained in nonpregnant patients.<sup>[147-149]</sup>

#### 4.2 Nonsteroidal Anti-Inflammatory Drugs

NSAIDs may be used as analgesics during pregnancy. Their occasional use does not appear to increase the natural risks of pregnancy.<sup>[150]</sup> With use of NSAIDs during the third trimester oligohydramnios and anuria in the fetus have been observed, as well as early closure of Botallo's duct with possible pulmonary hypertension, intracranial haemorrhage, and necrotising enterocolitis in the neonate; consequently they are contraindicated.<sup>[151-157]</sup>

#### 4.3 Benzodiazepines

Benzodiazepines are included in the most commonly used antianxiety drugs. Administration during pregnancy must be clinically justified; a benzodiazepine with a short half-life and devoid of active metabolites is to be preferred. Administration during early pregnancy seems to be associated with a slight increase in cleft lip with or without cleft palate<sup>[158]</sup> while, among the effects of high doses of benzodiazepines given in the immediate pre-partum period, apnoea, hypotonia, hypothermia, neonatal withdrawal syndrome with signs and

symptoms of neuromuscular excitability predominate.<sup>[158-161]</sup>

### 5. Conclusions

While congenital defects induced by pharmaceuticals represent only a small percentage of all anomalies, the fact that they can potentially be prevented is important. Considering that approximately 40% of pregnancies occur without any specific planning by the couple, any fertile woman should only use a drug when and if it is absolutely necessary because, while only few drugs have been demonstrated as teratogenic, all new drugs may be teratogenic. An excellent precaution would be to avoid prescribing multivitamin products containing high doses of retinol. When chronic therapies with drugs potentially harmful to the fetus are needed, the possibility of therapeutic changes in the pre-conception period by using alternative drugs, equally efficacious for the mother but with less risk for the fetus, should be carefully evaluated. Only when it is strictly necessary, and no equally efficacious alternative exists, should pharmaceuticals considered to be teratogenic be used. In this situation the possibility of a pregnancy should be excluded at the beginning of therapy, fertility should be controlled during pregnancy, and information on eventual waiting periods should be provided. If therapy is required during pregnancy, the risk/benefit ratio of the pharmacological action in relation to effects on fetus and embryo should be well assessed, taking into account the gestation period (in particular, the first trimester and peripartum). The absolutely safe drug does not exist, therefore it is preferable, when necessary, to administer drugs of proven efficacy and about which the risks associated with their use in pregnancy are already known.

In this regard it is to be hoped that TIS will soon be available in every country so as to provide adequate information for patients and medical staff. In such a service, personnel with special experience in clinical teratology, pharmacology and prenatal medicine would be able to provide pre-conception counselling, evaluate the teratogenic risk of a phar-

macological therapy during pregnancy, or advise on the best and safest drug for any necessary therapy to be continued during pregnancy.

## References

- Beckman DA, Brent RL. Mechanism of teratogenesis. *Annu Rev Pharmacol Toxicol* 1984; 24: 483-500
- Cordero JF, Oakley GP. Drug exposure during pregnancy: some epidemiologic considerations. *Clin Obstet Gynecol* 1983; 26: 418-28
- Shepard TH. Catalog of teratogenic agents. 8th ed. Baltimore: Johns Hopkins University Press, 1995
- Koren G. Maternal-fetal toxicology: a clinician's guide. 2nd ed. New York: Marcel Dekker Inc., 1994
- Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 5th ed. Baltimore: Williams & Wilkins, 1998
- Paulus WE. Pharmacotherapy in pregnancy. *Ther Umsch* 1999 Oct; 56 (10): 602-7
- Leck IM, Millard ELM. Incidence of malformations since the introduction of thalidomide. *BMJ* 1962; 2: 16-20
- McBride WG. Thalidomide embryopathy. *Teratology* 1977; 16: 79-82
- Newman CGH. The thalidomide syndrome: risks of exposure and spectrum of malformations. *Clin Perinatol* 1986; 13 (3): 555-73
- Neiger BL. The re-emergence of thalidomide: results of a scientific conference. *Teratology* 2000 Dec; 62 (6): 432-5
- Peuckmann V, Fisch M, Bruera E. Potential novel uses of thalidomide: focus on palliative care. *Drugs* 2000 Aug; 60 (2): 273-92
- Teratology society public affairs committee position paper: thalidomide. *Teratology* 2000 Sep; 62 (3): 172-3
- Lary JM, Daniel KL, Erickson JD, et al. The return of thalidomide: can birth defects be prevented? *Drug Saf* 1999 Sep; 21 (3): 161-9
- Schardein JL. Chemical induced birth defects. 2nd ed. New York: Marcel Dekker Inc., 1993: 228-49
- Zeldis JB, Williams BA, Thomas SD, et al. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. *Clin Ther* 1999 Feb; 21 (2): 319-30
- Kamm JJ. Toxicology, carcinogenicity, and teratogenicity of some orally administered retinoids. *J Am Acad Dermatol* 1982 Apr; 6 (4 Pt 2): 652-9
- Lammer EJ, Chen DT, Hoear RM, et al. Retinoic acid embryopathy. *N Engl J Med* 1985; 313: 837-41
- Rosa FW. Teratogenicity of isotretinoin [letter]. *Lancet* 1983; II: 513
- Rosa FW, Wilk AL, Kelsey FO. Teratogen update: vitamin A congeners. *Teratology* 1986; 33: 355-64
- Isotretinoin-A newly recognized human teratogen. *MMWR Morb Mortal Wkly Rep* 1984; 33: 171-3
- Strauss JS, Cunningham WJ, Leyden JJ, et al. Isotretinoin and teratogenicity. *J Am Acad Dermatol* 1988; 19: 353-4
- Thomson EJ, Cordero JF. The new teratogens: accutane and other vitamin-A analogs. *MCN Am J Matern Child Nurs* 1989; 14: 244-8
- Chen DT, Jacobson MM, Kuntzman RG. Experience with the retinoids in human pregnancy. In: Volans GN, editor. *Basic science in toxicology*. London: Francis Taylor Publishing Co., 1990; 473-82
- Lynberg MC, Khoury MJ, Lammer EJ, et al. Sensitivity, specificity, and positive predictive value of multiple malformations in isotretinoin embryopathy surveillance. *Teratology* 1990; 42: 513-9
- Khoury MJ, James LM, Lynberg MC. Quantitative analysis of associations between birth defects and suspected human teratogens. *Am J Med Genet* 1991; 40 (4): 500-5
- Teratology Society. Recommendations for isotretinoin use in women of childbearing potential. *Teratology* 1991; 44: 1-6
- Coberly S, Lammer E, Alashari M. Retinoic acid embryopathy: case report and review of literature. *Pediatr Pathol Lab Med* 1996; 16: 823-36
- Adverse effects with isotretinoin. *FDA Drug Bull.* 1983 Nov, 13 (3): 21-3
- Accutane-exposed pregnancies-California 1999. *MMWR Morb Mortal Wkly Rep* 2000 Jan 21; 49 (2): 28-31
- Autret E, Radal M, Jonville-Bera AP, et al. Isotretinoin (Roaccutane) in women of childbearing age: failure of following prescription guidelines. *Ann Dermatol Venerol* 1997; 124 (8): 518-22
- Atanackovic G, Koren G. Young women taking isotretinoin still conceive: role of physicians in preventing disaster. *Can Fam Physician* 1999; Feb; 45: 289-92
- Hatcher L. Who's heard of the Pregnancy Prevention Program? *Can Fam Physician* 1999 Apr; 45: 871-2
- Atanackovic G, Koren G. Fetal exposure to oral isotretinoin: failure to comply with the Pregnancy Prevention Program. *CMAJ* 1999; Jun 15, 160: 1719-20
- Kallen B. Restriction of the use of drugs with teratogenic properties: Swedish experiences with isotretinoin [letter]. *Teratology* 1999 Aug; 60 (2): 53
- Orfanos CE, Ehlert R, Gollnick H. The retinoids: a review of their clinical pharmacology and therapeutic use. *Drugs* 1987; 34: 459-503
- Griffiths CE, Clark CM, Chalmers RJ, et al. A systematic review of treatment for severe psoriasis. *Health Technol Assess* 2000; 4 (40): 1-125
- Di Giovanna JJ, Zech LA, Ruddel ME, et al. Etretinate: Persistent serum levels of a potent teratogen [abstract]. *Clin Res* 1984; 32: 579A
- Guillonnet M, Jacqz-Aigrain E. Teratogenic effects of vitamin A and its derivatives. *Arch Pediatr* 1997 Sep; 4 (9): 867-74
- Roche scientific summary: the clinical evaluation of Tegisoin. Basel: Roche Laboratories, Division of Hoffmann-La Roche Inc., 1986: 16-7
- Etretinate approved. *FDA drug Bull* 1986; 16-7
- Geiger JM, Baudin M, Saurat JH. Teratogenic risk with etretinate and acitretin treatment. *Dermatology* 1994; 189: 109-16
- de-Die Smulders CE, Sturkenboom MC, Veraart J, et al. Severe limb defects and craniofacial anomalies in a fetus conceived during acitretin therapy. *Teratology* 1995 Oct; 52 (4): 215-9
- Jacobsson C. Teratological studies on craniofacial malformations. *Swed Dent J Suppl* 1997; 121: 3-84
- Kubota Y, Shimotake T, Iwai N. Congenital anomalies in mice induced by etretinate. *Eur J Pediatr Surg* 2000; Aug; 10 (4): 248-51
- Camera G, Pregliasco P. Ear malformation in baby born to mother using tretinoin cream [letter]. *Lancet* 1992 Mar; 339 (8794): 687
- Lipson AH, Collins F, Webster WS. Multiple congenital defects associated with maternal use of topical tretinoin [letter]. *Lancet* 1993 May 22; 341 (8856): 1352-3
- Autret E, Berjot M, Jonville-Bera AP, et al. Anophthalmia and agenesis of optic chiasma associated with adapalene gel in early pregnancy [letter]. *Lancet* 1997 Aug 2; 350 (9074): 339

48. Birth defects due to topical adapalene and tretinoin. *Prescrire Int* 1998; Oct; 7 (37): 148-9
49. Selcen D, Seidman S, Nigro MA. Otcerebral anomalies associated with topical tretinoin use. *Brain Dev* 2000 Jun; 22 (4): 218-20
50. Jick SS, Terris BZ, Jick H. First trimester topical tretinoin and congenital disorders. *Lancet* 1993; 341: 1181-82
51. Shapiro L, Pastuszak A, Curto G, et al. Safety of first-trimester exposure to topical tretinoin: prospective cohort study. *Lancet* 1997 Oct; 18: 1143-4
52. Monga M. Vitamin A and its congeners. *Semin Perinatol* 1997 Apr; 21 (2): 135-42
53. Wiegand UW, Hartmann S, Hummler H. Safety of vitamin A: recent results. *Int J Vitam Nutr Res* 1998; 68 (6): 411-6
54. Teratology Society position paper: recommendations for vitamin A use during pregnancy. *Teratology* 1987 Apr; 35 (2): 269-75
55. Hathcock JN, Hattan DG, Jenkins MY, et al. Evaluation of vitamin A toxicity. *Am J Clin Nutr* 1990; 52: 183-202
56. Rothman KJ, Moore LL, Singer MR, et al. Teratogenicity of high vitamin intake. *N Engl J Med* 1995 Nov 23; 333 (21): 1369-73
57. Mastroiaco P, Mazzone T, Addis A, et al. High vitamin A intake in early pregnancy and major malformations: a multicenter prospective controlled study. *Teratology* 1999 Jan; 59 (1): 7-11
58. Schou M. What happened later to the lithium babies? A follow-up study of children born without malformations. *Acta Psychiatr Scand* 1976; 54: 193-7
59. Jacobson SJ, Jones K, Johnson K, et al. A prospective multicenter study of pregnancy outcome following lithium exposure during the first trimester of pregnancy. *Lancet* 1992; 339: 530-3
60. Cohen LS, Friedman JM, Jefferson JW, et al. A reevaluation of risk of in utero exposure to lithium. *JAMA* 1994; 271 (2): 146-50
61. Moore JA. An assessment of lithium using the IEHR evaluative process for assessing human developmental and reproductive toxicity of agents. *Reprod Toxicol* 1995; 9 (2): 175-210
62. Llewellyn A, Stowe ZN, Strader Jr JR. The use of lithium and management of women with bipolar disorder during pregnancy and lactation. *J Psychiatry* 1998; 59 (6): 57-64
63. Lanczik M, Knoche M, Fritze J. Nervenarzt psychopharmacotherapy during pregnancy and lactation. I: pregnancy. *Nervenarzt* 1998; Jan; 69 (1): 1-9
64. Warner JP. Evidence-based psychopharmacology 3: assessing evidence of harm: what are the teratogenic effects of lithium carbonate? *J Psychopharmacol* 2000 Mar; 14 (1): 77-80
65. Krause S, Ebbesen F, Lange AP. Polyhydramnios with maternal lithium treatment. *Obstet Gynecol* 1990; 75: 504-6
66. Nishiwaki T, Tanaka K, Sekiya S. Acute lithium intoxication in pregnancy. *Int J Gynaecol Obstet* 1996; 52: 191-2
67. McBride WG. Limb deformities associated with iminodibenzyl hydrochloride [letter]. *Med J Aust* 1972 Mar 4; 1 (10): 492
68. Rachelefsky GS, Flynt Jr JW, Ebbin AS, et al. Possible teratogenicity of tricyclic antidepressants. *Lancet* 1972; I: 838-9
69. Morrow AW. Limb deformities associated with iminodibenzyl hydrochloride. *Med J Aust* 1972; 1: 658-9
70. Heinonen OP, Slone D, Shapiro S. *Birth Defect and Drugs in Pregnancy*. Littleton (MA): John Wright-PSG, 1977
71. Brunel P, Vial T, Roche I, et al. First-trimester exposure to antidepressant drugs: result of a follow-up. *Therapie* 1994; 49: 117-22
72. McElhatton PR, Garbis HM, Elefant E, et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants: a collaborative study of the European Network of Teratology Information Service (ENTIS). *Reprod Toxicol* 1996; 10 (4): 285-94
73. Ericson A, Kallen B, Wiholm BE. Delivery outcome after use of antidepressants in early pregnancy. *Eur J Clin Pharmacol* 1999; 55: 503-8
74. Edlung MJ, Craig TJ. Antipsychotic drug use and birth defects: an epidemiologic reassessment. *Compr Psychiatry* 1984; 25: 32-7
75. Casey DE. Tardive dyskinesia. In Meltzer HY, editor. *Psychopharmacology: the third generation of progress*. New York: Raven Press; 1987: 1411-7
76. Cohen LS, Heller VL, Rosenbaum JF. Treatment guidelines for psychotropic drug use in pregnancy. *Psychosomatics* 1989; 30: 389-405
77. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. *N Engl J Med* 2001, Apr; 344: 1132-38
78. Kaneko S, Otani K, Kondo T, et al. Malformation in infants of mothers with epilepsy receiving antiepileptic drugs. *Neurology* 1992; 42 (4 Suppl. 5): 68-74
79. Tanganelli P, Regesta G. Epilepsy, pregnancy, and major birth anomalies: an Italian prospective, controlled study. *Neurology*. 1992 Apr; 42 (4 Suppl. 5): 89-93
80. Nakken Ko, Johannessen SI, Henriksen O. Epilepsy and pregnancy. *Tidsskr Nor Laegeforen* 1999; 119: 3437-40
81. Folb PI, Dukes MNG. *Drug safety in pregnancy*. Amsterdam: Elsevier Science Publishers BV, 1990: 87-109
82. Kelly TE. Teratogenicity of anticonvulsant drugs. I: review of the literature. *Am J Med Genet* 1984; 19: 413-34
83. Kelly TE, Edwards P, Rein M, et al. Teratogenicity of anticonvulsant drugs. II: a prospective study. *Am J Med Genet* 1984; 19: 435-43
84. Hanson JW. Teratogen update: fetal hydantoin effects. *Teratology* 1986; 33: 349-53
85. Rodriguez-Palmares C, Belmont-Gomez A, Amancio-Chassin O, et al. Phenytoin serum concentration monitoring during pregnancy and puerperium in Mexican epileptic women. *Arch Med Res* 1995; 26 (4): 371-7
86. Koren G, Demitrakoudis D, Weksberg R, et al. Neuroblastoma after prenatal exposure to phenytoin: cause and effect? *Teratology* 1989 Aug; 40 (2): 157-62
87. al-Shammri S, Guberman A, Hsu E. Neuroblastoma and fetal exposure to phenytoin in a child without dysmorphic features. *Can J Neurol Sci* 1992 May; 19 (2): 243-5
88. Satge D, Sasco AJ, Little J. Antenatal therapeutic drug exposure and fetal/neonatal tumours: review of 89 cases. *Paediatr Perinat Epidemiol* 1998 Jan; 12 (1): 84-117
89. Czeizel AE, Bod M, Halasz P. Teratogenic evaluation of anticonvulsants during pregnancy in a population-based Hungarian study. *Eur J Epidemiol* 1992 Jan; 8 (1): 122-7
90. Jones KL, Johnson KA, Adams J, et al. Teratogenic effects of carbamazepine. *N Engl J Med* 1989; 321: 1480-1
91. Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. *N Engl J Med* 1991 Mar 7; 324 (10): 674-7
92. Gladstone DJ, Bologna M, Maguire C, et al. Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin: a prospective study. *Reprod Toxicol* 1992; 6 (3): 257-61
93. Lindhout D, Omtzigt JGC. Teratogenic effects of antiepileptic drugs: Implications for the management of epilepsy in women of childbearing age. *Epilepsia* 1994; 35 Suppl. 4: S19-28

94. Omtzigt JG, Los FJ, Meijer JW, et al. The 10,11-epoxide-10,11-diol pathway of carbamazepine in early pregnancy in maternal serum, urine, and amniotic fluid: effect of dose, comedication, and relation to outcome of pregnancy. *Ther Drug Monit* 1993 Feb; 15 (1): 1-10
95. Kaneko S, Otani K, Kondo T, et al. Teratogenicity of antiepileptic drugs and drug specific malformations. *Jpn J Psychiatry Neurol* 1993; 47: 306-8
96. Robert E, Robert JM, Lapras C. Is valproic acid teratogenic? *Rev Neurol* 1983; 139: 445-7
97. Lammer EJ, Sever LE, Oakley Jr GP. Teratogen update: valproic acid: *Teratology* 1987; 35: 465-73
98. Robert E. Valproic acid as a human teratogen. *Cong Anom* 1988; 28 Suppl.: S71-S80
99. Kallen B, Robert E, Mastroiacovo P, et al. Anticonvulsant drugs and malformations: is there a drug specificity? *Eur J Epidemiol* 1989; 5 (1): 31-6
100. Samren EB, Van Duijzen CM, Koch S, et al. Maternal use of antiepileptic drugs and risk of major congenital malformation: a joint European prospective study of human teratogenesis associated with maternal epilepsy. *Epilepsia* 1997; 38 (9): 981-90
101. Canger R, Battino D, Canevini MP, et al. Malformation in offspring of women with epilepsy: prospective study. *Epilepsia* 1999; 40 (9): 1231-6
102. Rodriguez-Pinilla E, Arroyo I, Fondevilla J, et al. Prenatal exposure to valproic acid during pregnancy and limb deficiencies: a case-control study. *Am J Med Genet* 2000; 90: 376-81
103. Delgado-Escueta AV, Janz D. Consensus guidelines: preconception counselling, management, and care of the pregnant woman with epilepsy. *Neurology* 1992; 42 (4 Suppl. 5): 149-60
104. Samren EB, Van Duijn CM, Christiansen GCML, et al. Antiepileptic drug regimens and major congenital abnormalities in the offspring. *Ann Neurol* 1999; 46: 739-46
105. Shapiro S, Hartz SC, Siskind V, et al. Anticonvulsants and parental epilepsy in the development of birth defects. *Lancet* 1976; I: 272-5
106. Dansky LV, Finnell RH. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: epidemiologic and experimental findings spanning three decades 2: human studies. *Reprod Toxicol* 1991; 5 (4): 301-35
107. Waters CH, Belai Y, Gott PS, et al. Outcomes of pregnancy associated with antiepileptic drugs. *Arch Neurol* 1994; 51: 250-3
108. Jones KL, Johnson KA, Chamber CC. Pregnancy outcome in women treated with fenobarbital monotherapy. *Teratology* 1992; 45: 452-3
109. Reinisch JM, Sanders SA, Mortensen EL, et al. In utero exposure to phenobarbital and intelligence deficits in adult men. *JAMA* 1995 Nov 15; 274: 1518-25
110. Wing DA, Millar LK, Koonings PP, et al. A comparison of propylthiouracil versus methimazole in the treatment of hyperthyroidism in pregnancy. *Am J Obstet Gynecol* 1994; 170: 90-5
111. Mandel SJ, Brent GA, Larsen PR. Review of antithyroid drug use during pregnancy and report of a case of aplasia cutis. *Thyroid* 1994; 4 (1): 129-33
112. Sargent KA, Stopfer JE, Mallozzi AE, et al. Apparent scalp-ear-nipple (Findlay) syndrome in a neonate exposed to methimazole in utero [abstract]. *Am J Hum Genet* 1994; 55 (3 Suppl.): A312
113. Vogt T, Stolz W, Landthaler M. Aplasia cutis congenita after exposure to methimazole: a causal relationship? *Br J Dermatol* 1995; 133: 994-6
114. Clementi M, Di Gianantonio E, Pelo E, et al. Methimazole embryopathy: delineation of the phenotype. *Am J Med Genet* 1999; 83: 43-6
115. Wilson LC, Kerr BA, Wilkinson R, et al. Chonal atresia and hypotelia following methimazole exposure in utero: a second report. *Am J Med Genet* 1998; 75: 220-2
116. Day RE, Insley J. Maternal diabetes mellitus and congenital malformation: survey of 205 cases. *Arch Dis Child* 1976; 51: 935-8
117. Beard RW, Lowry C. The British survey of diabetic pregnancies. *Br J Obstet Gynaecol* 1982; 89: 783-6
118. Mills JL. Malformation in infants of diabetic mothers. *Teratology* 1982; 25: 385-94
119. Leslie RDG, Pyke DA, John PN, et al. Hemoglobin A1c in diabetic pregnancy. *Lancet* 1978; II: 958-9
120. Mills JL, Baker L, Goldman A. Malformations in infants of diabetic mothers occur before the seventh gestational week. Implications for treatment. *Diabetes* 1979; 28: 292-3
121. Sadler TW. Effects of maternal diabetes on early embryogenesis. II: hyperglycemia-induced exencephaly. *Teratology* 1980; 21: 349-56
122. Miller E, Hare JW, Cloherty JP, et al. Elevated maternal hemoglobin A1c in early pregnancy and major congenital anomalies in infants of diabetic mothers. *N Engl J Med* 1981; 304: 1331-4
123. Eriksson U, Dahlstrom E, Larsson KS, et al. Increased incidence of congenital malformations in the offspring of diabetic rats and their prevention of maternal insulin therapy. *Diabetes* 1982; 31: 1-6
124. Fuhrmann K, Reiher H, Semmler K, et al. Prevention of congenital malformations in infants of insulin-dependent diabetic mothers. *Diabetes Care* 1983; 6: 219-23
125. Caruso A, Ferrazzani S, De Carolis S. *Medicina materno-fetale: protocolli di assistenza*. Rome: Società Editrice Universo, 1994: 387-93
126. Quenneville G, Barton B, McDevitt E, et al. The use of anticoagulants for thrombophlebitis during pregnancy. *Am J Obstet Gynecol* 1959; 77: 1135-49
127. Villasanta U. Thromboembolic disease in pregnancy. *Am J Obstet Gynecol* 1965; 93: 142-60
128. Warkany J. Warfarin embryopathy. *Teratology* 1976; 14: 205-10
129. Iturbe-Alessio I, Fonseca MC, Mutchinik O, et al. Risks of anticoagulant therapy in pregnant women with artificial heart valves. *N Engl J Med* 1986 Nov 27; 315 (22): 1390-3
130. Ginsberg JS, Hirsh J, Turner DC, et al. Risks to the fetus of anticoagulant therapy during pregnancy. *Thromb Haemostasis* 1989 Apr 25; 61 (2): 197-203
131. Ginsberg JS, Kowalchuk G, Hirsh J, et al. Heparin therapy during pregnancy: risks to the fetus and mother. *Arch Intern Med* 1989 Oct; 149 (10): 2233-6
132. Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. *Am J Med* 1980 Jan; 68 (1): 122-40
133. Russo R, Bortolotti U, Schivazappa L, et al. Warfarin treatment during pregnancy: a clinical note. *Haemostasis* 1979; 8: 96-8
134. Ounsted M, Cockburn J, Moar VA, et al. Maternal hypertension with superimposed pre-eclampsia: effects on child development at 7½ years. *Br J Obstet Gynaecol* 1983 Jul; 90 (7): 644-9
135. Guignard JP, Burgener F, Calame A. Persistent anuria in a neonate: a side effect of captopril [abstract]? *Int J Pediatr Nephrol* 1981; 2 (2): 133

136. Duminy PC, Burger PD. Fetal abnormality associated with the use of captopril during pregnancy [abstract]. *S Afr Med J* 1981 Nov 21; 60 (21): 805
137. Rothberg AD, Lorenz R. Can captopril cause fetal and neonatal renal failure? *Pediatr Pharmacol (New York)* 1984; 4 (3): 189-92
138. Boutroy MJ. Fetal effects of maternally administered clonidine and angiotensin-converting enzyme inhibitors. *Dev Pharmacol Ther* 1989; 13 (2-4): 199-204
139. Rosa FW, Bosco LA, Graham CF, et al. Neonatal anuria with maternal angiotensin-converting enzyme inhibition. *Obstet Gynecol* 1989 Sep; 74 (3 Pt 1): 371-4
140. Barr M, Cohen MM. ACE inhibitor fetopathy and hypocalvaria: the kidney-skull connection. *Teratology* 1991 Nov; 44 (5): 485-95
141. Hanssens M, Keirse MJ, Vankelecom F, et al. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. *Obstet Gynecol* 1991 Jul; 78 (1): 128-35
142. Piper JM, Ray WA, Rosa FW. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors. *Obstet Gynecol* 1992; 80: 429-32
143. Pryde PG, Sedman AB, Nugent CE, et al. Angiotensin-converting enzyme inhibitor fetopathy. *J Am Soc Nephrol* 1993 Mar; 3 (9): 1575-82
144. Sedman AB, Kershaw DB, Bunchman TE. Recognition and management of angiotensin converting enzyme inhibitor fetopathy. *Pediatr Nephrol* 1995 Jun; 9 (3): 382-5
145. Mastrobattista JM. Angiotensin converting enzyme inhibitors in pregnancy. *Semin Perinatol* 1997 Apr; 21 (2): 124-34
146. Saji H, Yamanaka M, Hagiwara A, et al. Losartan and fetal toxic effects [letter]. *Lancet* 2001; 357: 363
147. Glantz JC. Reproductive toxicology of alkylating agents. *Obstet Gynecol Surv* 1994; 49: 709-15
148. Doll DC, Ringenberg QS, Yarbrow GW. Antineoplastic agents and pregnancy. *Semin Oncol* 1989; 16: 337-46
149. Zemlickis D, Lishner M, Degendorfer P, et al. Fetal outcome after in utero exposure to cancer chemotherapy. *Arch Intern Med* 1992; 152: 573-6
150. Kallen B. The teratogenicity of antirheumatic drugs: what is the evidence? *Scand J Rheumatol Suppl* 1998; 107: 119-24
151. Van den Veyver IB, Moise KJ, Ou CN, et al. The effect of gestational age and fetal indomethacin levels on the incidence of constriction of the fetal ductus arteriosus. *Obstet Gynecol* 1993 Oct; 82 (4 Pt 1): 500-3
152. Lione A, Scialli AR. The developmental toxicity of indomethacin and sulindac. *Obstet Gynecol Surv* 1993 Jul; 48 (7): 493-502
153. Major CA, Lewis DF, Harding JA, et al. Tocolysis with indomethacin increases the incidence of necrotizing enterocolitis in the low-birth-weight neonate. *Am J Obstet Gynecol* 1994 Jan; 170 (1 Pt 1): 102-6
154. Norton ME, Merrill J, Cooper BA, et al. Neonatal complications after the administration of indomethacin for preterm labor. *N Engl J Med* 1993 Nov 25; 329 (22): 1602-7
155. Van den Veyver IB, Moise KJ. Prostaglandin synthetase inhibitors in pregnancy. *Reprod Toxicol* 1995 Jan-Feb; 9 (1): 7-20
156. Iannucci TA, Besinger RE, Fisher SG, et al. Effect of dual tocolysis on the incidence of severe intraventricular hemorrhage among extremely low-birth-weight infants. *Am J Obstet Gynecol* 1996 Oct; 175 (4 Pt 1): 1043-6
157. Norton ME. Teratogen update: fetal effects of indomethacin administration during pregnancy. *Teratology* 1997 Oct; 56 (4): 282-92
158. Safra MJ, Oakley Jr GP. Valium: an oral cleft teratogen. *Cleft Palate J* 1976; 13: 198-200
159. Laegreid L, Hagberg G, Lundberg A. The effect of benzodiazepines on the fetus and the newborn. *Neuropediatrics* 1992 Feb; 23 (1): 18-23
160. Kanjilal S, Pan NR, Chakraborty DP, et al. Cord blood diazepam: clinical effects in neonates of eclamptic mothers. *Indian J Pediatr* 1993 Mar-Apr; 60 (2): 257-63
161. Dixon JC, Speidel BD, Dixon JJ. Neonatal flumazenil therapy reverses maternal diazepam. *Acta Paediatr* 1998 Feb; 87 (2): 225-6

---

Correspondence and offprints: Dr *Marco De Santis*, Department of Obstetrics and Gynaecology, Catholic University of Sacred Heart, Largo A. Gemelli, 8, 00168 Rome, Italy.  
E-mail: marco.desantis15@tin.it